NAMS
NewAmsterdam Pharma Company N.V.
There isn't enough reported data to score NAMS yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NAMS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
NAMS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NAMS PE Valuation
NAMS has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
NAMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NAMS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NAMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.68 | +$0.33 |
| Q2 2026 | -$2.15 | -$0.57 |
| Q1 2026 | -$1.78 | +$0.06 |
| Q4 2025 | -$1.72 | +$0.84 |
| Q3 2025 | -$2.01 | +$0.16 |
| Q2 2025 | -$1.58 | +$0.97 |
| Q1 2025 | -$1.84 | +$0.73 |
| Q4 2024 | -$2.56 | -$0.58 |
NAMS is still losing money, but far less than before: $1.68 per share over the past year, against $3.66 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over NAMS on earnings quality, reporting a profit while its opponent remains loss making.
NAMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.2M | +5407% |
| Q2 2026 | $3.7M | -81% |
| Q1 2026 | $3M | +2.1% |
| Q4 2025 | $32K | -100% |
| Q3 2025 | $348K | -99% |
| Q2 2025 | $19.1M | +740% |
| Q1 2025 | $3M | +113% |
| Q4 2024 | $12.8M | +1491% |
NAMS's revenue is recovering but still below its 2022 peak: $19M last quarter, up 5407% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -231% | +15615 points |
| Q2 2026 | -1753% | -1567 points |
| Q1 2026 | -1922% | +393 points |
| Q4 2025 | -206188% | -205849 points |
| Q3 2025 | -15846% | -15760 points |
| Q2 2025 | -186% | +2121 points |
| Q1 2025 | -2314% | +1646 points |
| Q4 2024 | -338% | +6022 points |
NAMS's operating margin was −231% last quarter, up 15615 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over NAMS on profitability, with a higher operating margin.
NAMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40M | -$7.1M |
| Q2 2026 | -$39.3M | -$1.5M |
| Q1 2026 | -$30.6M | +$5.8M |
| Q4 2025 | -$41M | -$3.5M |
| Q3 2025 | -$32.8M | -$20.2M |
| Q2 2025 | -$37.8M | +$16.4M |
| Q1 2025 | -$36.5M | +$18.5M |
| Q4 2024 | -$37.5M | -$4.4M |
NAMS has burned cash in almost every quarter: −$151M over the past year, against −$145M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over NAMS on cash generation, producing positive trailing cash flow while its opponent burns cash.
NAMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +766K shares |
| 1 year | +4.3% | +5.1M shares |
| 3 years | +51% | +41.7M shares |
| 5 years | +44% | +38M shares |
NAMS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NAMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -55.9x | Net Cash |
| Q2 2022 | -2.7x | Net Cash |
| Q1 2022 | -16.5x | Net Cash |
NAMS has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NAMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 10.1 | Oversold |
NAMS's weekly RSI is 34 (neutral) and its Stochastic is 10 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NAMS PE vs Healthcare Sector
| Metric | NAMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NAMS has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NAMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.7 | 3.7% below |
| 20 week MA | $25.2 | 21% below |
| 50 week MA | $30.0 | 33% below |
| 100 week MA | $27.3 | 27% below |
| 200 week MA | $21.4 | 6.6% below |
NAMS is in a downtrend: it's below all five of its weekly moving averages, and 6.6% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NAMS on trend strength, trading above more of its moving averages.
NAMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.6 | $9.74 | -8.5% |
| 2022 | $9.74 | $11.3 | +16% |
| 2023 | $11.3 | $11.2 | -1.2% |
| 2024 | $11.2 | $25.9 | +132% |
| 2025 | $25.9 | $35.3 | +36% |
| 2026 YTD | $35.3 | $20.0 | -43% |
NAMS is down 43% so far in 2026, after finishing higher in three of the previous five years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NAMS on returns for 2026, with the stronger performance.